HUP0101419A2 - Integrinek receptorokhoz való kötődésének gátlására szolgáló vegyületek, valamint ezeket tartalmazó gyógyászati készítmények - Google Patents
Integrinek receptorokhoz való kötődésének gátlására szolgáló vegyületek, valamint ezeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0101419A2 HUP0101419A2 HU0101419A HUP0101419A HUP0101419A2 HU P0101419 A2 HUP0101419 A2 HU P0101419A2 HU 0101419 A HU0101419 A HU 0101419A HU P0101419 A HUP0101419 A HU P0101419A HU P0101419 A2 HUP0101419 A2 HU P0101419A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- compounds
- binding
- heterocyclic
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102220517591 Methyl-CpG-binding domain protein 3-like 2B_R11C_mutation Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229910018828 PO3H2 Inorganic materials 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 102000029719 integrin binding proteins Human genes 0.000 abstract 1
- 108091009291 integrin binding proteins Proteins 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
A tal lm ny t rgy t az (I) ltal nos képletű vegyületek és ezek gyógyszatilag megfelelő sói és prekurzorjai képezik. Az (I) ltal nosképletű vegyületek szelektíven g tolj k az a4<1 integrin k"tődésétemlős"kben; ennek k"vetkeztében eredményesen adhatók olyan betegségekkezelésére, amelyeknél az a4<1, integrin k"tése szerepet j tszik; ezekk"zül említik meg péld ul a gyullad sos betegségeket, asztm t, a reums, ízületi gyullad st, az I típusú diabetest és a r kosmegbetegedéseket. Az (I) ltal nos képletben A jelentése O, S vagy NR5;E jelentése CH2, O, S vagy NR6; Q jelentése C(O) vagy (CH2)k, ahol kértéke 0 vagy 1; J jelentése O, S vagy NR8; G jelentése O, NH, S vagy(CH2)p, ahol p értéke 0 vagy 1; T jelentése C(O) vagy (CH2)b, ahol bértéke 0, 1, 2 vagy 3; L jelentése O, NR7, S vagy (CH2)n, ahol nértéke 0 vagy 1; M jelentése C(R9)(R10) vagy (CH2)u, ahol u értéke 0,1, 2 vagy 3; X jelentése CO2B, PO3H2, SO3H, OPO3H2, C(O)NHC(O)R11C(O)NHSO2R12, tetrazolilcsoport vagy hidrogénatom; B R1 R2 R3 R4 R5 R6R7 R8 R9 R10 R11 és R12 jelentése egym stól függetlenül hidrogénatom,alkil-, cikloalkil-, aril-, hidroxi-alkil-, alkoxi-, alkoxi-alkoxi-,cikloalkil-alkil-, alkil-amino-, halogén-alkil-, alkil-aril-, aril-alkil-, heterociklusos, alkil-heterociklusos vagy heterociklusos-alkilcsoport, ahol R2 és R3 együttesen gyűrűt képezhet; R4 és R7együttesen gyűrűt képezhet; R9 és R10 együttesen gyűrűt képezhet. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8201998P | 1998-04-16 | 1998-04-16 | |
| PCT/US1999/008305 WO1999052493A2 (en) | 1998-04-16 | 1999-04-15 | Compounds that inhibit the binding of integrins to their receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101419A2 true HUP0101419A2 (hu) | 2002-04-29 |
| HUP0101419A3 HUP0101419A3 (en) | 2002-08-28 |
Family
ID=22168519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101419A HUP0101419A3 (en) | 1998-04-16 | 1999-04-15 | Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them |
| HU0103752A HUP0103752A3 (en) | 1998-04-16 | 1999-04-15 | N,n-disubstituted amides and pharmaceutical compositions containing them that inhibit the binding of integrins to their receptors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103752A HUP0103752A3 (en) | 1998-04-16 | 1999-04-15 | N,n-disubstituted amides and pharmaceutical compositions containing them that inhibit the binding of integrins to their receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US6096773A (hu) |
| EP (2) | EP1071680B1 (hu) |
| JP (2) | JP4753403B2 (hu) |
| KR (2) | KR20010042704A (hu) |
| CN (2) | CN1311676A (hu) |
| AT (2) | ATE474573T1 (hu) |
| AU (2) | AU3748399A (hu) |
| BR (2) | BR9909625A (hu) |
| CA (2) | CA2328234C (hu) |
| DE (2) | DE69939165D1 (hu) |
| ES (2) | ES2345471T3 (hu) |
| HU (2) | HUP0101419A3 (hu) |
| ID (1) | ID28658A (hu) |
| IL (2) | IL138973A0 (hu) |
| NO (2) | NO20005161L (hu) |
| NZ (1) | NZ507534A (hu) |
| PL (2) | PL343770A1 (hu) |
| SK (2) | SK15592000A3 (hu) |
| TR (2) | TR200100139T2 (hu) |
| WO (2) | WO1999052898A1 (hu) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306909B1 (en) | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| KR20010042704A (ko) | 1998-04-16 | 2001-05-25 | 데이비드 비. 맥윌리암스 | 인테그린이 인테그린 수용체에 결합하는 것을 억제하는ｎ,ｎ-이치환된 아미드 |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| DE60036918D1 (de) | 1999-01-22 | 2007-12-13 | Elan Pharm Inc | Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren |
| WO2000043371A2 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| CN1231212C (zh) | 1999-01-22 | 2005-12-14 | 依兰制药公司 | 抑制vla－4介导的白细胞粘着的多环化合物 |
| US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| WO2000051974A1 (en) | 1999-03-01 | 2000-09-08 | Elan Pharmaceuticals, Inc. | Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 - receptor antagonists |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| WO2001012183A1 (en) * | 1999-08-16 | 2001-02-22 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| PL357109A1 (en) | 1999-12-28 | 2004-07-12 | Pfizer Products Inc. | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| DE60141889D1 (de) * | 2000-02-03 | 2010-06-02 | Eisai R&D Man Co Ltd | Inhibitoren der integrinexpression |
| EP1273571A4 (en) * | 2000-04-14 | 2003-05-02 | Kureha Chemical Ind Co Ltd | NITROGEN COMPOUNDS AND ANTIVIRAL MEDICATIONS CONTAINING THEM |
| AU2001248553A1 (en) | 2000-04-17 | 2001-10-30 | Celltech R And D Limited | Enamine derivatives as cell adhesion molecules |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| DE10063173A1 (de) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| CN1630517A (zh) * | 2001-05-24 | 2005-06-22 | 吴羽化学工业株式会社 | 包含含氮化合物的具有cxcr4拮抗作用的药物 |
| CA2448160A1 (en) * | 2001-05-25 | 2002-12-05 | Queen's University At Kingston | Heterocyclic beta-amino acids and their use as anti-epileptogenic agents |
| JPWO2003029218A1 (ja) * | 2001-09-28 | 2005-01-13 | 呉羽化学工業株式会社 | 新規含窒素化合物及びその用途 |
| SI21096B (sl) * | 2001-10-09 | 2012-05-31 | Encysive Pharmaceuticals Inc | Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| CN1703395A (zh) * | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| KR100863667B1 (ko) | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | 아민 화합물 및 그 용도 |
| US7459472B2 (en) * | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| JP2007501844A (ja) * | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US8227434B1 (en) | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| EP1724263B1 (en) * | 2004-03-10 | 2014-03-05 | Kureha Corporation | Basic amine compound and use thereof |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7615556B2 (en) * | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| EP2303308A4 (en) | 2008-05-13 | 2012-11-07 | Clarassance Inc | HUMAN RECOMBINANT PROTEIN CC10 AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF NASAL RHINITIS |
| TWI433838B (zh) * | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| US9168285B2 (en) | 2009-10-15 | 2015-10-27 | Therabron Therapeutics, Inc. | Recombinant human CC10 protein for treatment of influenza and ebola |
| NZ599511A (en) | 2009-10-15 | 2014-06-27 | Clarassance Inc | Recombinant human cc10 protein for treatment of influenza |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| CA2818336C (en) | 2010-11-16 | 2018-04-24 | Texas Heart Institute | Agonists that enhance binding of integrin-expressing cells to integrin receptors |
| WO2015136468A1 (en) | 2014-03-13 | 2015-09-17 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| MX2017000082A (es) | 2014-07-01 | 2017-05-30 | 7 Hills Interests Llc | Composiciones y metodos para mejorar terapias con celulas adoptivas. |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US20210393811A1 (en) * | 2018-10-05 | 2021-12-23 | Texas Heart Institute | Imaging Agents and Methods of Use |
| CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| CA3115830C (en) | 2018-10-30 | 2023-09-12 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| AU2019373240B2 (en) | 2018-10-30 | 2023-04-20 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4372974A (en) * | 1980-06-25 | 1983-02-08 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
| US5654301A (en) * | 1985-02-15 | 1997-08-05 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5378729A (en) * | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| ZW6189A1 (en) * | 1988-05-09 | 1990-05-09 | Smithkline Beckman Corp | Anti-aggregatory peptides |
| EP0422398A3 (en) | 1989-10-12 | 1992-07-08 | International Business Machines Corporation | A method of optimizing a computer program by removing invariant branches from loops |
| NZ235563A (en) * | 1989-10-13 | 1993-04-28 | Merck & Co Inc | Fibrinogen receptor antagonist and pharmaceutical composition |
| NZ235564A (en) | 1989-10-13 | 1993-10-26 | Merck & Co Inc | Fibrinogen receptor antagonist and pharmaceutical compositions |
| US5192746A (en) * | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| JPH06192273A (ja) * | 1992-10-26 | 1994-07-12 | Lederle Japan Ltd | カルバペネム−３−カルボン酸エステル誘導体 |
| WO1994022820A1 (en) | 1993-03-31 | 1994-10-13 | G.D. Searle & Co. | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors |
| JPH06298797A (ja) * | 1993-04-12 | 1994-10-25 | Fuji Photo Film Co Ltd | ペプチド誘導体およびその用途 |
| JP3190765B2 (ja) * | 1993-05-13 | 2001-07-23 | 富士写真フイルム株式会社 | ペプチド誘導体及びその用途 |
| US5936065A (en) | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| WO1995015973A1 (en) * | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
| US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| US5811391A (en) * | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| JP2920741B2 (ja) * | 1994-12-14 | 1999-07-19 | 参天製薬株式会社 | 新規１，３−ジアルキルウレア誘導体 |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| JP2000516596A (ja) * | 1996-07-25 | 2000-12-12 | バイオジェン，インコーポレイテッド | 細胞接着インヒビター |
| WO1999006434A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| DK1027328T3 (da) * | 1997-10-31 | 2006-11-13 | Aventis Pharma Ltd | Substituerede anilider |
| GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| KR20010033248A (ko) * | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| KR20010042704A (ko) | 1998-04-16 | 2001-05-25 | 데이비드 비. 맥윌리암스 | 인테그린이 인테그린 수용체에 결합하는 것을 억제하는ｎ,ｎ-이치환된 아미드 |
-
1999
- 1999-04-15 KR KR1020007011423A patent/KR20010042704A/ko not_active Application Discontinuation
- 1999-04-15 AT AT99917544T patent/ATE474573T1/de not_active IP Right Cessation
- 1999-04-15 BR BR9909625-0A patent/BR9909625A/pt not_active IP Right Cessation
- 1999-04-15 WO PCT/US1999/008302 patent/WO1999052898A1/en not_active Application Discontinuation
- 1999-04-15 ES ES99917544T patent/ES2345471T3/es not_active Expired - Lifetime
- 1999-04-15 PL PL99343770A patent/PL343770A1/xx not_active Application Discontinuation
- 1999-04-15 JP JP2000543106A patent/JP4753403B2/ja not_active Expired - Fee Related
- 1999-04-15 HU HU0101419A patent/HUP0101419A3/hu unknown
- 1999-04-15 NZ NZ507534A patent/NZ507534A/en unknown
- 1999-04-15 TR TR2001/00139T patent/TR200100139T2/xx unknown
- 1999-04-15 CN CN99808487A patent/CN1311676A/zh active Pending
- 1999-04-15 DE DE69939165T patent/DE69939165D1/de not_active Expired - Lifetime
- 1999-04-15 AT AT99919856T patent/ATE402170T1/de not_active IP Right Cessation
- 1999-04-15 CA CA002328234A patent/CA2328234C/en not_active Expired - Fee Related
- 1999-04-15 DE DE69942610T patent/DE69942610D1/de not_active Expired - Lifetime
- 1999-04-15 BR BR9909626-9A patent/BR9909626A/pt not_active IP Right Cessation
- 1999-04-15 CA CA2328990A patent/CA2328990C/en not_active Expired - Fee Related
- 1999-04-15 SK SK1559-2000A patent/SK15592000A3/sk unknown
- 1999-04-15 CN CN99807342A patent/CN1305473A/zh active Pending
- 1999-04-15 IL IL13897399A patent/IL138973A0/xx unknown
- 1999-04-15 AU AU37483/99A patent/AU3748399A/en not_active Abandoned
- 1999-04-15 HU HU0103752A patent/HUP0103752A3/hu unknown
- 1999-04-15 TR TR2001/00141T patent/TR200100141T2/xx unknown
- 1999-04-15 WO PCT/US1999/008305 patent/WO1999052493A2/en not_active Application Discontinuation
- 1999-04-15 AU AU35637/99A patent/AU3563799A/en not_active Abandoned
- 1999-04-15 KR KR1020007011406A patent/KR20010087125A/ko not_active Application Discontinuation
- 1999-04-15 US US09/292,459 patent/US6096773A/en not_active Expired - Lifetime
- 1999-04-15 EP EP99919856A patent/EP1071680B1/en not_active Expired - Lifetime
- 1999-04-15 JP JP2000543456A patent/JP4949552B2/ja not_active Expired - Fee Related
- 1999-04-15 ID IDW20002066A patent/ID28658A/id unknown
- 1999-04-15 SK SK1560-2000A patent/SK15602000A3/sk not_active Application Discontinuation
- 1999-04-15 IL IL13897299A patent/IL138972A0/xx unknown
- 1999-04-15 ES ES99919856T patent/ES2308839T3/es not_active Expired - Lifetime
- 1999-04-15 PL PL99346220A patent/PL346220A1/xx unknown
- 1999-04-15 EP EP99917544A patent/EP1079825B1/en not_active Expired - Lifetime
- 1999-10-14 US US09/417,886 patent/US6262084B1/en not_active Expired - Lifetime
- 1999-10-14 US US09/417,857 patent/US6194448B1/en not_active Expired - Lifetime
-
2000
- 2000-10-13 NO NO20005161A patent/NO20005161L/no not_active Application Discontinuation
- 2000-10-13 NO NO20005162A patent/NO20005162L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0101419A2 (hu) | Integrinek receptorokhoz való kötődésének gátlására szolgáló vegyületek, valamint ezeket tartalmazó gyógyászati készítmények | |
| HUP9800138A2 (hu) | 8-Helyettesített-1,3,8-triaza-spiro[4.5]dekán-4-on-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0103111A2 (hu) | Epotilonszármazékok, eljárás az előllításukra és alkalmazásuk | |
| HUP0203458A2 (hu) | Nociceptin ORL-1 receptor agonisták alkalmazása köhögés kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
| TR200401007T4 (tr) | Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları | |
| HUP9904204A2 (hu) | Naftiridinszármazékok,valamint ezeket tartalmazó,többek között asztma kezelésére adható gyógyászati készítmények, intermedierek | |
| HUP0104662A2 (hu) | Kombinált 5HT1A, 5HT1B és 5HT1D receptor antagonista aktivitással rendelkező kinolinszármazékok, eljárás az előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| BR9609888A (pt) | Halogenobenzimidazóis | |
| HUP0002476A2 (hu) | Aminvegyületek, előállításuk és alkalmazásuk | |
| HUP0203836A2 (hu) | 1,3-Diszubsztituált pirrolidin-származékok alfa2-adrenerg-receptor antagonista hatással, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| BR9604821A (pt) | Novos derivados de arillicinamida processos para a sua preparação e composições farmacêuticas contendo estes compostos | |
| HUP0103896A2 (hu) | Oxigéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| ATE196293T1 (de) | Triazole enthaltende antifungizide mittel | |
| HUP0001865A2 (hu) | Amino-pirimidin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302115A2 (hu) | Tiazabiciklo[3.2.2]nonán-fenil-izoxazol-származékok, előállításuk és ezeket tartalamzó gyógyszerkészítmények | |
| PT80507A (de) | Neue substituierte bis-(4-aminophenyl)-sulfone ihre herstellungund ihre verwendung als arzneimittel | |
| IL71788A0 (en) | Pyridazinones,processes for their preparation and pharmaceutical compositions containing the same | |
| DE69720715D1 (en) | Hexahydro-pyrido (4,3-b)indolderivate als antipsychotische arzneimittel | |
| GB9610031D0 (en) | Chemical compounds | |
| IL115184A0 (en) | Anthracycline derivatives their preparation and use | |
| HUP0402033A2 (hu) | 2-Amino-4-piridil-metil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| ATE16106T1 (de) | Chroman-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| HUP0003689A2 (hu) | Endotelin antagonista benzotiazin-dioxid-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás ismert származékok előállítására | |
| BR9507289A (pt) | Derivados de éster e carbamato de azolonas com atividade anti-heli-cobacteriana | |
| FI972530A (fi) | Menetelmä substituoitujen 4-etyyli-piperidiinien valmistamiseksi ja niiden valmistuksessa käytettävä välituote |